Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2021 | 3 |
2022 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
Ann Hematol. 2021 Mar;100(3):691-698. doi: 10.1007/s00277-021-04429-8. Epub 2021 Feb 2.
Ann Hematol. 2021.
PMID: 33528609
Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations.
Gusak A, Fedorova L, Lepik K, Volkov N, Popova M, Moiseev I, Mikhailova N, Baykov V, Kulagin A.
Gusak A, et al. Among authors: fedorova l.
Cancers (Basel). 2021 Nov 12;13(22):5676. doi: 10.3390/cancers13225676.
Cancers (Basel). 2021.
PMID: 34830831
Free PMC article.
Item in Clipboard
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV, Lepik KV, Volkov NP, Kotselyabina PV, Borzenkova ES, Popova MO, Beynarovich AV, Baykov VV, Kozlov AV, Moiseev IS, Mikhailova NB, Kulagin AD.
Fedorova LV, et al.
Int J Clin Oncol. 2022 Mar;27(3):626-632. doi: 10.1007/s10147-021-02085-6. Epub 2021 Nov 26.
Int J Clin Oncol. 2022.
PMID: 34826011
Free PMC article.
Item in Clipboard
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Lepik KV, Fedorova LV, Kondakova EV, Zalyalov YR, Babenko EV, Lepik EE, Kotselyabina PV, Beynarovich AV, Popova MO, Volkov NP, Stelmakh LV, Baykov VV, Moiseev IS, Mikhailova NB, Kulagin AD, Afanasyev BV.
Lepik KV, et al. Among authors: fedorova lv.
Hemasphere. 2020 Sep 23;4(5):e480. doi: 10.1097/HS9.0000000000000480. eCollection 2020 Oct.
Hemasphere. 2020.
PMID: 33062947
Free PMC article.
Item in Clipboard
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV.
Lepik KV, et al. Among authors: fedorova lv.
Hemasphere. 2020 Jun 8;4(3):e401. doi: 10.1097/HS9.0000000000000401. eCollection 2020 Jun.
Hemasphere. 2020.
PMID: 32647803
Free PMC article.
Item in Clipboard
Cite
Cite